Financial Snapshot: Analyzing Janux Therapeutics Inc (JANX)’s Key Ratio Metrics

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

The closing price of Janux Therapeutics Inc (NASDAQ: JANX) was $49.99 for the day, up 2.19% from the previous closing price of $48.92. In other words, the price has increased by $2.19 from its previous closing price. On the day, 0.86 million shares were traded. JANX stock price reached its highest trading level at $50.075 during the session, while it also had its lowest trading level at $47.915.

Ratios:

Our analysis of JANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 62.09 and its Current Ratio is at 62.09. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 21, 2024, initiated with a Buy rating and assigned the stock a target price of $62.

On March 20, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.

On April 06, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $24.Wedbush initiated its Outperform rating on April 06, 2023, with a $24 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’23 when Avalon Ventures XI, L.P. bought 849,854 shares for $5.87 per share. The transaction valued at 4,988,643 led to the insider holds 849,854 shares of the business.

Reardon Tighe bought 849,854 shares of JANX for $4,988,643 on Nov 13 ’23. The Acting Chief Financial Officer now owns 849,854 shares after completing the transaction at $5.87 per share. On Nov 13 ’23, another insider, Lichter Jay, who serves as the Director of the company, bought 849,854 shares for $5.87 each. As a result, the insider paid 4,988,643 and bolstered with 849,854 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2592016640 and an Enterprise Value of 1964148352. For the stock, the TTM Price-to-Sale (P/S) ratio is 355.55 while its Price-to-Book (P/B) ratio in mrq is 3.95. Its current Enterprise Value per Revenue stands at 269.541 whereas that against EBITDA is -27.732.

Stock Price History:

Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 9.87%, while the 200-Day Moving Average is calculated to be 158.98%.

Shares Statistics:

JANX traded an average of 1.10M shares per day over the past three months and 1005500 shares per day over the past ten days. A total of 46.25M shares are outstanding, with a floating share count of 34.56M. Insiders hold about 33.35% of the company’s shares, while institutions hold 59.66% stake in the company. Shares short for JANX as of 1714435200 were 3301160 with a Short Ratio of 3.00, compared to 1711584000 on 3753826. Therefore, it implies a Short% of Shares Outstanding of 3301160 and a Short% of Float of 12.659999999999998.

Most Popular

[the_ad id="945"]